Manatt Health Partner Michael Kolber was quoted in InsideHealthPolicy on how the Centers for Medicare & Medicaid Services’ (CMS) first round of negotiated prices for Medicare drugs under the Inflation Reduction Act (IRA) may influence how states implementing prescription drug affordability boards (PDABs) set their own pricing limits.
The article discussed how PDABs may use the new maximum fair prices to set limits on how much drugs can cost in their states. “Several states that have implemented PDABs are realizing that regulating drug prices is complicated and difficult,” Kolber said. “We know that at least Minnesota has already enacted a law that would require that the Medicare ‘maximum fair price’ to be used if the board sets an upper payment limit for a drug that has been selected for IRA ‘negotiation.’ Several other states are considering similar laws.”
InsideHealthPolicy subscribers can read the full article here.